Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · IEX Real-Time Price · USD
9.85
+0.05 (0.51%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Company Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.
Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline.
Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Amicus Therapeutics, Inc.
| Country | United States |
| Founded | 2002 |
| IPO Date | May 31, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 517 |
| CEO | Bradley L. Campbell M.B.A. |
Contact Details
Address: 3675 Market Street Philadelphia, Pennsylvania 19104 United States | |
| Phone | (215) 921-7600 |
| Website | amicusrx.com |
Stock Details
| Ticker Symbol | FOLD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001178879 |
| CUSIP Number | 03152W109 |
| ISIN Number | US03152W1099 |
| Employer ID | 20-0422823 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Bradley L. Campbell M.B.A. | Chief Executive Officer, President and Director |
| Ellen S. Rosenberg | Chief Legal Officer and Corporate Secretary |
| David M. Clark | Chief People Officer |
| Dr. Jeffrey P. Castelli | Chief Development Officer |
| Simon Nicolas Reade Harford | Chief Financial Officer |
| Samantha Prout | Chief Accounting Officer and Controller |
| Dr. Jill Weimer Ph.D. | Chief Science Officer |
| Andrew Faughnan | Senior Director of Investor Relations |
| Patrik S. Florencio Esq. | Global Chief Compliance and Risk Officer |
| Diana Moore | Head of Global Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2024 | 144 | Filing |
| Jun 7, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 7, 2024 | 8-K | Current Report |
| Jun 3, 2024 | 144 | Filing |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| May 1, 2024 | 144 | Filing |
| Apr 24, 2024 | ARS | Filing |
| Apr 24, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2024 | DEF 14A | Other definitive proxy statements |